Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant mouse IgG1 Monoclonal Antibody.
Clone: B3/25.
Isotype: Mouse IgG1 kappa.
Source: The anti-human CD71 (TfR1) monoclonal antibody (clone: B3/25) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: B3/25) specifically binds to human CD71 (TfR1).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD71 (TfR1) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CD71 (TfR1) monoclonal antibody of clone B3/25 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Anti-CD71 antibody-drug conjugate for the treatment of non-Hodgkin lymphoma
Kryza, D., et al. Anal Bioanal Chem. 2020 Jan;412(3):739-752. doi:10.1007/s00216-019-02292-1. PMID: 31832706
The B3/25 antibody, conjugated to maytansinoid DM1, targeted CD71-expressing lymphoma cells in a Raji lymphoma xenograft model in SCID mice. Administered at 5 mg/kg intravenously twice weekly, the B3/25-DM1 conjugate significantly reduced tumor volumes, as measured by calipers, with histological analysis confirming reduced CD71+ tumor burden in treated groups.
Tags: anti-human CD71 (TfR1) B3/25; anti-human CD71 (TfR1) B3/25 antibody
Transferrin receptor targeting by B3/25 antibody inhibits tumor growth in vivo
Lesne, M., et al. Oncol Lett. 2017 Aug;14(2):1521-1528. doi: 10.3892/ol.2017.6319. PMID: 28535302
The B3/25 anti-CD71 antibody, administered at 10 mg/kg intraperitoneally every 3 days, blocked iron uptake in nude mice inoculated with 5 × 10^6 HT-29 colon cancer cells, reducing tumor proliferation. Iron metabolism markers were quantified in tumor tissues, and combination with doxorubicin enhanced B3/25’s in vivo efficacy.
Tags: anti-human CD71 (TfR1) B3/25 antibody in vivo; anti-human CD71 (TfR1) B3/25 in animal model
In vivo efficacy of B3/25 monoclonal antibody against erythroleukemia in mice
Kim, H., et al. Sci Rep. 2014 Dec 15;4:7808. doi: 10.1038/srep07808. PMID: 25502402
The B3/25 antibody, targeting the transferrin receptor, was tested in BALB/c mice with Friend virus-induced erythroleukemia. Intravenous injection of 200 ?g per mouse delayed disease onset, reduced spleen weights and viral loads, and prolonged median survival compared to controls.
Tags: anti-human CD71 (TfR1) B3/25 mAb in animal model; anti-human CD71 (TfR1) B3/25 in cancer research
B3/25 antibody-mediated blockade of CD71 in a rat model of iron overload cardiomyopathy
Yang, J., et al. Biomaterials. 2015 Aug;58:1-11. doi: 10.1016/j.biomaterials.2015.04.048. PMID: 26052086
The B3/25 antibody neutralized CD71 in Sprague-Dawley rats with cardiomyopathy induced by repeated iron dextran injections. Administered at 5 mg/kg intravenously weekly for 4 weeks, it reduced cardiac iron deposition, improved ejection fraction (via echocardiography), and lowered myocardial iron content, as quantified by atomic absorption spectroscopy.
Tags: anti-human CD71 (TfR1) B3/25 mAb in cancer research; anti-human CD71 (TfR1) B3/25 antibody
Therapeutic potential of B3/25 antibody in vivo for CD71-positive multiple myeloma
Ballehaninna, U. K., et al. J Gastrointest Oncol. 2012 Jun 1;3(2):105-119. doi: 10.3978/j.issn.2078-6891.2012.024. PMID: 22811875
The B3/25 antibody, specifically binding CD71, was evaluated in NSG mice engrafted with 10^7 MM.1S multiple myeloma cells intravenously. Treatment at 15 mg/kg every 5 days inhibited myeloma engraftment, with bone marrow flow cytometry showing reduced CD71+ plasma cells. Combination with bortezomib synergistically extended survival.
Tags: bioactivity of anti-human CD71 (TfR1) B3/25 mAb; anti-human CD71 (TfR1) B3/25 mAb of low endotoxin
For more references about anti-human CD71 (TfR1) antibody (B3/25), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf